Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Expression of NF-κB, EGFR, and HER3 in castration-resistant prostate adenocarcinoma: a clinical and molecular study of 88 Moroccan patients].

The Pan African medical journal·2026
Same author

Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.

CNS drugs·2026
Same author

Deep Brain Stimulation for Dystonia: Experience of a Moroccan University Hospital.

Pediatric neurology·2023
Same author

Lack of Association of <i>C677T</i> Methylenetetrahydrofolate Reductase Polymorphism with Breast Cancer Risk in Mali.

Genetics research·2023
Same author

Association of the <i>Interleukin-10-592C/A</i> Polymorphism and Cervical Cancer Risk: A Meta-Analysis.

Genetics research·2022
Same author

Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.

Pharmacogenetics and genomics·2022

Related Experiment Video

Updated: May 31, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Prothrombin G20210A and factor V Leiden polymorphisms in stroke.

Thierry Paluku They-They1, Omar Battas, Ilham Slassi

  • 1Laboratory of Genetic and Molecular Pathology, Medical School, Hassan II University, 19, rue Tarik-Ibn-Ziad, BP 9154, 10000, Casablanca, Morocco. thierrypal@yahoo.fr

Journal of Molecular Neuroscience : MN
|June 25, 2011
PubMed
Summary

The prothrombin G20210A mutation is a modest genetic risk factor for large artery disease stroke in Morocco. Factor V Leiden mutation was not found in the study population.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 31, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

  • Neuroscience
  • Genetics
  • Epidemiology

Background:

  • Molecular epidemiology of stroke is understudied in developing nations.
  • Understanding genetic predispositions to stroke is crucial for targeted prevention strategies.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms (prothrombin G20210A and factor V Leiden) and ischemic stroke risk in Casablanca, Morocco.
  • To identify specific stroke subtypes linked to these genetic factors.

Main Methods:

  • Case-control study involving 91 ischemic stroke patients and 182 healthy controls from Casablanca.
  • Genotyping for prothrombin G20210A mutation and factor V Leiden.
  • Assessment of conventional vascular risk factors.

Main Results:

  • No significant overall association between prothrombin G20210A mutation and ischemic stroke.
  • A significant association was found between prothrombin G20210A mutation and the large artery disease stroke subtype (p=0.046).
  • This association remained strong after adjusting for conventional risk factors (adjusted OR, 4.3; p=0.029).
  • Factor V Leiden mutation was not detected in the study cohort.

Conclusions:

  • Prothrombin G20210A mutation may be a modest genetic risk factor for the large artery disease stroke subtype in the Moroccan population.
  • Factor V Leiden is not associated with stroke risk in this population.
  • Further research is needed to elucidate the role of genetic factors in stroke epidemiology in developing regions.